Accolade Inc (STU:4NE1)
€ 3.42 0.12 (3.64%) Market Cap: 275.12 Mil Enterprise Value: 279.28 Mil PE Ratio: 0 PB Ratio: 0.70 GF Score: 61/100

Accolade Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 08, 2021 / 07:50PM GMT
Release Date Price: €42.55 (+2.16%)
Robert Patrick Jones
Goldman Sachs Group, Inc., Research Division - VP

Okay. Good afternoon, everyone. Welcome to the Accolade session. I am Bob Jones. I'm joined by my colleague, Kevin Hartman. We cover health care services and IT here at Goldman. Very excited for this next session with Accolade. Joining us from the company, we have Raj Singh, CEO; Steve Barnes, CFO; as well as Todd Freeman, SVP of IR.

So obviously, idea today clearly trying to keep it as conversational as possible; a lot to cover, obviously. But I thought, Raj, maybe for starters, just given that there has been a couple of recent deals the company has done or announced, I thought that would be a good place to start, just to make sure we have the opportunity to kind of level set the folks on the line and all the investors out there as far as the rationale behind some of these deals and kind of what made them exciting for Accolade right now.

Questions & Answers

Robert Patrick Jones
Goldman Sachs Group, Inc., Research Division - VP

So maybe just to start with PlushCare, the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot